T-Therapeutics, a biotech firm specializing in T cell receptor therapeutics, raised an additional $32 million in Series A funding, bringing its total to $91 million, with aims to advance its innovative cancer and autoimmune disease treatments.

Information on the Target

T-Therapeutics is a biotechnology company spun out from Cambridge University, focusing on the development of innovative T cell receptor (TCR) therapeutics aimed at treating cancer and autoimmune diseases. The company has recently raised an additional $32 million, bringing its total Series A funding to $91 million. This funding will significantly enhance its capability to advance its promising drug pipeline.

The company’s principal asset in oncology targets a pan-tumour driver, making it applicable across various solid tumor types. In the realm of immunology, its lead program focuses on a bispecific that aims to achieve precision immune modulation through the selective depletion of harmful immune cells.

Industry Overview in the Target’s Specific Country

The biotechnology sector in the United Kingdom has been thriving, particularly in regions like Cambridge, known for its rich academic resources and cutting-edge research initiativ